Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$63.04
−$0.75 · -1.18%
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Previous close
$63.04
−$0.75 · -1.18%
Pre-market
$63.11
+$0.07 · +0.11%
Oct 8, 4:03 AM ET
Regular session · ET · Market data may be delayed.
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Day range
Current $63.04
52-week range
Current $63.04
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
8
Overpriced
Sentiment
57
Mixed
Risk
56
Elevated Risk
Momentum
70
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Day range
Current $63.04
52-week range
Current $63.04
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 379.81M USD | 333.79M USD | 280.32M USD | 321.79M USD | 296.4M USD |
| Cost of goods sold | 123.24M USD | 109.63M USD | 102M USD | 112.21M USD | 97.39M USD |
| Gross profit | 256.57M USD | 224.16M USD | 178.33M USD | 209.58M USD | 199.01M USD |
| Research and development | 71.43M USD | 72.41M USD | 81.87M USD | 90.39M USD | 76.53M USD |
| Selling, general, and administrative | 210.21M USD | 205.5M USD | 201.2M USD | 196.42M USD | 152.21M USD |
| Operating expenses | 281.64M USD | 183.39M USD | 381.69M USD | 286.81M USD | 228.73M USD |
| Interest income | 9.17M USD | 11.77M USD | 11.87M USD | 3.76M USD | 160K USD |
| Depreciation and amortization | 20.42M USD | 19.76M USD | 19.82M USD | 16.01M USD | 11.89M USD |
| Operating income | −25.07M USD | 40.77M USD | −203.36M USD | −77.23M USD | −29.73M USD |
| Net income | −21.35M USD | 52.55M USD | −190.28M USD | −76.61M USD | −30.66M USD |
Company facts updated Oct 8, 2026.
Funds reporting this stock among their holdings, ordered by reported position size.
ARK Genomic Revolution ETFARKG90.65M4.30%1.56B USD0.75%$50.14-3.11%
State Street SPDR S&P Biotech ETFXBI88.28M0.86%10.08B USD0.35%$150.23-0.44%
iShares Russell 2000 ETFIWM85.51M0.11%78.56B USD0.19%$277.7-1.29%
Vanguard Morningstar Total Stock Market ETFVTI77.99M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 Growth ETFIWO30.65M0.22%14.25B USD0.24%$355.37-1.43%
Vanguard Extended Market ETFVXF30.1M0.03%95.4B USD0.05%$233.49-1.56%
Dimensional - US Small Cap ETFDFAS25.46M0.07%34.14B USD0.31%$77.92-1.38%
iShares Biotechnology ETFIBB22.83M0.22%10.4B USD0.44%$203.34+0.12%ARK Genomic Revolution ETFARKGState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
